Advanced Search

 

Study ID Status Title Patient Level Data
213503/044 Completed Open study to assess the immunogenicity after two and three doses of GSK Biologicals’ Hib vaccine combined with GSK Biologicals’ DTPa-IPV vaccine given to Swedish infants in a 3, 5, 12 month schedule Study Listed on ClinicalStudyDataRequest.com
213503/045 Completed Study to compare immunogenicity and reactogenicity of GSK Bio’s DTPa-IPV vaccine, with GSK Bio’s DTPa (Infanrix) and Aventis MSDs IPV vaccine (Imovax Polio) administered separately to healthy children 4 to 6 years of age Study Listed on ClinicalStudyDataRequest.com
213503/046 Completed Open, randomised phase IIIb, clinical trial to compare the immunogenicity and reactogenicity of GSK Biologicals’ DTaP-IPV vaccine, with GSK Biologicals’ DTaP and Aventis Pasteur MSD’s IPV vaccines administered to healthy children, previously vaccinated with 4 doses of DTaP and polio vaccines, and co-administered with GSK Biologicals’ MMR vaccine Study Listed on ClinicalStudyDataRequest.com
213503/047 Completed Open, randomized, phase II, clinical trial to compare the immunogenicity and safety of a booster dose of GSK Biologicals' DTaP-IPV vaccine (Infanrix®-IPV) co-administered with a booster dose of Merck and Company's M-M-R®II, to that of separate injections of GSK Biologicals' DTaP vaccine (Infanrix®), Aventis Pasteur's IPV (IPOL®) and M-M-R®II administered as booster doses to healthy children 4 to 6 years of age. Study Listed on ClinicalStudyDataRequest.com
213503/048 Completed Safety, immunogenicity&consistency of 3 manufacturing lots of DTaP-IPV vaccine vs separate injections of GSK Biologicals' DTaP + Aventis Pasteur's IPV admd as booster doses to healthy children 4-6 yrs, each co-admd with Merck's MMR vaccine Study Listed on ClinicalStudyDataRequest.com
213503/049 Completed An open, multicentre, phase IV booster vaccination study to assess the immunogenicity and reactogenicity of GSKBiologicals combined Infanrix-IPV+Hib (DTPa-IPV/Hib) vaccine in healthy children aged 17 to 20 months whocompleted a three-dose primary vaccination course Study Listed on ClinicalStudyDataRequest.com
213503/050 Completed Study to evaluate safety and immunogenicity of a booster dose of DTPa-IPV/Hib at 18 months of age with GSK Biologicals DTPa-IPV/Hib compared to Aventis Pasteurs Pentacel, after an initial primary vaccination series administered at 2, 4, and6 months of age with Aventis Pasteurs Pentacel Study Listed on ClinicalStudyDataRequest.com
217744/001 Completed Open randomised clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine in comparison to SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B vaccine when co-administered with inactivated poliovirus vaccine as two separate injections in opposite limbs and administered as primary vaccinations to healthy infants at 3, 4 and 5 months of age
217744/002 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine. The vaccines will be administered as primary vaccinations to healthy infants at 2, 4, and 6 months of age
217744/004 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SmithKline Beecham Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine, co-administered with commercially available Haemophilus influenza type b vaccine as two separate injections in opposite limbs. The vaccines will be administered as primary vaccination to healthy infants at 2, 4 and 6 months of age
217744/010 Completed Open clinical study to evaluate the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, co-administered with SB Biologicals' Hib vaccine as two separate injections in opposite limbs
217744/011 Completed Randomised clinical study to assess the safety and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4 and 5 months
217744/012 Completed Randomised clinical study to assess the immunogenicity and reactogenicity of SB Biologicals' DTPa-HBV-IPV vaccine, when co-administered with Hib vaccine in two concomitant injections into opposite limbs, as a primary vaccination course to healthy infants at the age of 3, 4½ and 6 months
217744/015 Completed An open study of the safety and immunogenicity of DTPa-HBV-IPV vaccine administered as a three dose series or in a sequential IPV/OPV schedule at 2, 4, and 6 months of age
217744/028 Completed Study to assess the safety and reactogenicity of SB Biologicals DTPa vaccine, co-administered with commercial Hib vaccine as compared to SB Biologicals' DTPa vaccine-SB Biologicals' DTPa-IPV vaccine each time mixed with SB Biologicals’ Hib vaccine, and to SB Biologicals’ DTPa-HBV-IPV vaccine co-administered with SB Biologicals’ Hib vaccine
217744/030 Completed A phase III open randomised primary vaccination study of three doses of SB Biologicals’ DTPa-HBV-IPV vaccine co-administered with SB Biologicals’ Hib vaccine into opposite limbs, compared to commercially available DTPw-IPV/Hib vaccine co-administered with hepatitis B vaccine, in healthy children
217744/035 Completed A booster vaccination study of one dose of GSK’s DTPa HBV IPV vaccine, coadministered with 2 formulations of GSK’s Hib conjugate vaccine, either mixed or injected in 2 concomitant injections, in healthy children who participated in Study 217744/011 (DTPa-HBV-IPV-011) or 217744/016 (DTPa-HBV-IPV-016)
217744/049 Completed Immunogenicity and reactogenicity of GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines when administered concomitantly to healthy infants administered as a three-dose primary vaccination course at the age of 1.5, 3.5 and 6 months Study Listed on ClinicalStudyDataRequest.com
217744/054 Completed Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV vaccine mixed with Hib vaccine to healthy infants at 3, 5 and 11 months of age, compared to each vaccine administered separately
217744/060 Completed Study to assess the immunogenicity and reactogenicity of DTPa-HBV-IPV mixed with Hib vaccine in healthy infants, followed by a dose of the same vaccine administered simultaneously with one dose of oral polio vaccine (OPV) Study Listed on ClinicalStudyDataRequest.com
217744/061 Completed A phase II, single-blinded, randomized comparative study of the safety and immunogenicity of a booster dose of SmithKline Beecham Biologicals' DTPa-HBV-IPV vaccine compared with Infanrix™ when both vaccines are co-administered with OmniHIB™ between 15 and 18 months of age following primary immunization at the age of 2, 4 and 6 months in the study DTPa-HBV-IPV-044 (217744/044) Study Listed on ClinicalStudyDataRequest.com
217744/063 Completed Open, clinical study to assess the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine (DTPa-HBV-IPV) administered mixed in the same syringe with GSK Biologicals’ Haemophilus influenzae type b (Hib), tetanus conjugate vaccine in the 3rd and 5th month of life healthy infants, followed at the 11th month of life by a dose of the same GSK Biologicals’ DTPa-HBV-IPV and Hib vaccines mixed in the same syringe and administered simultaneously with one dose of oral poliovirus vaccine Study Listed on ClinicalStudyDataRequest.com
217744/066 Completed Open, randomized, multicentre, phase III clinical trial to assess the reactogenicity and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ DTPa-HBV-IPV/Hib vaccine, co-administered during the same visit with GSK Biologicals’ HAV vaccine (Havrix™), in children in their second year of life. Study Listed on ClinicalStudyDataRequest.com
217744/068 Completed Study to assess immunogenicity, safety and reactogenicity of GSK Biologicals DTPa-IPV/Hib and HBV vaccines compared to an investigational vaccination regimen in healthy infants born to hepatitis B surface antigen negative mothers and previously primed at birth with a dose of GSK Biologicals' hepatitis B vaccine Study Listed on ClinicalStudyDataRequest.com
217744/069 Completed Immunogenicity and safety of GSK Biological’s DTPa-HBV-IPV/Hib vaccine or DTPa-IPV/Hib co-administered with HBV vaccine as primary and booster vaccination in healthy infants born to hepatitis B surface antigen negative mothers Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.